DrugPatentWatch Database Preview

Incyte Corp Company Profile

« Back to Dashboard

What is the competitive landscape for INCYTE CORP, and when can generic versions of INCYTE CORP drugs launch?

INCYTE CORP has two approved drugs.

There are ten US patents protecting INCYTE CORP drugs.

There are two hundred and twenty-two patent family members on INCYTE CORP drugs in forty-eight countries and twenty-six supplementary protection certificates in seventeen countries.

Summary for Incyte Corp

International Patents:	222
US Patents:	10
Tradenames:	2
Ingredients:	2
NDAs:	2

Drugs and US Patents for Incyte Corp

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-001	Nov 16, 2011		RX	Yes	No
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-005	Nov 16, 2011		RX	Yes	Yes	10,016,429
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-002	Nov 16, 2011		RX	Yes	No	7,598,257		Y	Y
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-004	Nov 16, 2011		RX	Yes	No	8,829,013
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-003	Nov 16, 2011		RX	Yes	No	8,829,013
Incyte Corp	PEMAZYRE	pemigatinib	TABLET;ORAL	213736-002	Apr 17, 2020		RX	Yes	No
Incyte Corp	JAKAFI	ruxolitinib phosphate	TABLET;ORAL	202192-001	Nov 16, 2011		RX	Yes	No	8,722,693		Y	Y

Paragraph IV (Patent) Challenges for INCYTE CORP drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Tablets	5 mg, 10 mg, 15 mg, 20 mg, and 25 mg		2015-12-17

International Patents for Incyte Corp Drugs

Country	Patent Number	Estimated Expiration
Portugal	2348023
Cyprus	1116574
Cuba	20090213
Poland	3070090
Hong Kong	1168090
South Korea	101218214
Cuba	24179

Supplementary Protection Certificates for Incyte Corp Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1966202	8/2013	Austria		PRODUCT NAME: RUXOLITINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
2455382	PA2017012	Lithuania		PRODUCT NAME: RUKSOLITINIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/12/773/001-006 20150311
1966202	145 1-2013	Slovakia		FORMER OWNER: INCYTE CORPORATION, WILMINGTON, DE, US;
1966202	92137	Luxembourg		PRODUCT NAME: RUXOLITINIB,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
1966202	C300574	Netherlands		PRODUCT NAME: RUXOLITINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/12/773/001-003 20120823
1966202	SPC/GB13/005	United Kingdom		PRODUCT NAME: RUXOLITINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/12/773/001 20120828; UK EU/1/12/773/002 20120828; UK EU/1/12/773/003 20120828
1966202	CR 2013 00005	Denmark		PRODUCT NAME: RUXOLITINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, HERUNDER RUXOLITINIB PHOSFAT; REG. NO/DATE: EU/1/12/773/001-003 20120823

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Incyte Corp